Jan 12, 2022 / 04:15PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst
Hello. Good morning, everyone. This is Rachel Vatnsdal from JPM's Life Science Tools and Diagnostics team. I am pleased to present our next company, Amyris.
And so as a reminder, if you have any questions, please submit them via the Q&A function on the conference website.
And with that, let me turn it over to John.
John G. Melo - Amyris, Inc. - President, CEO & Director
Great, Rachel. Thank you and good morning, everyone. Thank you for joining us on this presentation.
I'd like to call out on the forward-looking statements on Slide 2. During today's presentation, I will be sharing preliminary unaudited revenue numbers for 2021. We may update these numbers at future investor events or as part of a news release, so I just wanted to let you all know that. And I will be using slides or calling out slide numbers so that you'll be able to follow me as I reference content during the presentation.
So let me step back and start with what Amyris
Amyris Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot